About zenas biopharma inc - ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
ZBIO At a Glance
Zenas BioPharma, Inc.
852 Winter Street
Waltham, Massachusetts 02451
| Phone | 1-857-271-2954 | Revenue | 10.00M | |
| Industry | Biotechnology | Net Income | -377,737,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 100.0% | |
| Fiscal Year-end | 12 / 2026 | Employees | 167 | |
| View SEC Filings |
ZBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 162.415 |
| Price to Book Ratio | 8.17 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.44 |
| Enterprise Value to Sales | 136.092 |
| Total Debt to Enterprise Value | 0.059 |
ZBIO Efficiency
| Revenue/Employee | 59,880.24 |
| Income Per Employee | -2,261,898.204 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.027 |
ZBIO Liquidity
| Current Ratio | 5.605 |
| Quick Ratio | 5.605 |
| Cash Ratio | 5.478 |
ZBIO Profitability
| Gross Margin | 99.44 |
| Operating Margin | -2,113.85 |
| Pretax Margin | -3,778.16 |
| Net Margin | -3,777.37 |
| Return on Assets | -100.248 |
| Return on Equity | -136.219 |
| Return on Total Capital | -117.271 |
| Return on Invested Capital | -119.223 |
ZBIO Capital Structure
| Total Debt to Total Equity | 33.022 |
| Total Debt to Total Capital | 24.825 |
| Total Debt to Total Assets | 20.843 |
| Long-Term Debt to Equity | 32.562 |
| Long-Term Debt to Total Capital | 24.479 |